Lexaria Bioscience (LEXX) EPS (Basic) Growth (1y) (2015 - 2026)
Lexaria Bioscience (LEXX) EPS (Basic) Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | -16.29% |
| 10 | Lexaria Bioscience | 10.14 Mn | 6.52 Mn | - | -47.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -63.00% |
| Feb 28, 2026 | -64.39% |
| Nov 30, 2025 | -79.65% |
| Aug 31, 2025 | -3.91% |
| May 31, 2025 | 233.04% |
| Feb 28, 2025 | 461.18% |
| Nov 30, 2024 | 413.76% |
| Aug 31, 2024 | 76.33% |
| May 31, 2024 | -65.13% |
| Feb 29, 2024 | -74.49% |
| Nov 30, 2023 | 144.93% |
| Aug 31, 2023 | 172.76% |
| May 31, 2023 | 193.05% |
| Feb 28, 2023 | -9.43% |
| Nov 30, 2022 | 15.22% |
| Aug 31, 2022 | 7.05% |
| May 31, 2022 | 20.07% |
| Feb 28, 2022 | 341.91% |
| Nov 30, 2021 | -50.09% |
| Aug 31, 2021 | -4.05% |